Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV004766503 | SCV005380857 | likely pathogenic | Persistent Mullerian duct syndrome | 2024-08-08 | criteria provided, single submitter | clinical testing | Variant summary: AMHR2 c.160C>T (p.Arg54Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.4e-05 in 250270 control chromosomes in the gnomAD database, including 1 homozygotes. This frequency is not significantly higher than estimated for a pathogenic variant in AMHR2 causing Persistent Mullerian duct syndrome, allowing no conclusion about variant significance. c.160C>T has been reported in the literature in the compound heterozygous state in at least 2 individuals affected with Persistent Mullerian duct syndrome (example, Imbeaud_1996, Tian_2022), including at least 1 individual carrying a pathogenic variant in trans. These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. In vitro experiments showed this variant prevented binding of the ligand protein (encoded by AMH) and also eliminated the activation of a target gene by AMH, suggesting the activation pathway is disrupted by this variant (example, Belville_2009). The following publications have been ascertained in the context of this evaluation (PMID: 19457927, 8872466, 34810374). No submitters have cited clinical-significance assessments for this variant to ClinVar. Based on the evidence outlined above, the variant was classified as likely pathogenic. |